VIR Stock — Vir Biotechnology, Inc.

Up next

Next earnings call

Aug 5, 2026 Scheduled · in 1 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 7, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Ask ALVIS about this →

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 18.2 · elevated Equity put/call 0.71

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +11%

above

Price vs 50-day avg −5%

below

RSI (14) 39

neutral

MACD trend Negative

52-week position 64%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −12%

trailing

6-month return +15%

trailing

YTD return +47%

this year

Relative strength +7%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $9 › 200d $8 — 50d above 200d

Institutional flow Accumulating

40 of 254 funds reported for Jun 30 · net +158.8K sh shares · +4 new

Insider flow Distributing

Net -$254.8K over 90 days · 100% sells

Short interest Falling

10.94% of float · ▼ -3.9% MoM · 12.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

254 holders — near 3-yr high, broad support

Squeeze score 68

elevated · 0–100

Fundamentals

Fair

Revenue growth −8%

Y/Y

EPS growth +17%

Y/Y

Free cash flow $-396.6M

Balance sheet $232.2M

net cash

Quant / Vol

risk profile

Very High

Volatility 70%

annualized · 1-yr

Max drawdown −26%

past year

ATR 5.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

1 · 5 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+11% Bullish

Price vs 50-day avg

−5% Neutral

RSI (14)

39 Neutral

MACD trend

Negative Bearish

52-week position

64% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $9 › 200d $8 — 50d above 200d

Institutional flow Accumulating

40 of 254 funds reported for Jun 30 · net +158.8K sh shares · +4 new

Insider flow Distributing

Net -$254.8K over 90 days · 100% sells

Short interest Falling

10.94% of float · ▼ -3.9% MoM · 12.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

254 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $4 Now $9 · 64% 52-wk high $12

vs 200-day avg +11% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Cash, cash equivalents and investments	$781M	Year-end 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
VIR Vir Biotechnology, Inc. this stock	$1.49B	+46.8%	-7.6%	—	10.9%
ONC BeOne Medicines Ltd.	$474.96B	+8.8%	+22179.2%	966.6	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$124.46B	+8.2%	+46.2%	29.1	2.0%
REGN Regeneron Pharmaceuticals, Inc.	$72.88B	-9.8%	+20.8%	17.0	3.3%
ARGX Argenx SE	$54.57B	+3.7%	—	—	2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

256

% held: 77.7%
Reported: 40 of 254
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

237

View

Short & Settlement

Short Interest Falling

Shares short

18.5M

Days to cover: 12.0d
Change: -739.8K sh

View

Short Volume

Short vol %

58%

As of: Jul 28, 2026

Short Total

View

Fails to Deliver

FTD shares

23.7K

Value: $237.4K
As of: Jun 29, 2026

View

Off-Exchange

Off-exchange %

43.2%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$254.8K

Buyers / Sellers: 0 / 3

Buyers Sellers

View

Financials

Revenue (FY)

$68.6M

Net income (FY): $-438.0M
EPS diluted: $-3.16

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 24, 2026
This year: 14

View

Proposed Sales

Value

$165.1K

Shares: 16.0K
Filed: Jun 29, 2026

View

Exempt Offerings

Offering

$32.4M

Filed: May 8, 2020

View

Earnings & Events

Earnings Calls Upcoming

Next call

Aug 5, 2026

Last call: May 6, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
VIR	-4.1%	-11.8%	+14.8%	-13.2%	+46.8%
SPY	-1.0%	0.0%	+7.4%	-0.8%	+8.6%
vs SPY	-3.1%	-11.7%	+7.4%	-12.4%	+38.1%

VIR · Vir Biotechnology, Inc.

Price & Indicators

Up next

AI Brief

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance